Director, Scientific and Medical Education

Waltham, Massachusetts, United States

Auto‑apply with AI Apply

Not SpecifiedCompensation

Junior (1 to 2 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, Medical EducationIndustries

Requirements

The Director, Scientific and Medical Education requires a Doctor’s degree (MD, PhD, PharmD) with a minimum of 10 years of experience, focusing on rare diseases, neuromuscular experience, or a related discipline. Candidates should possess analytical skills, demonstrated success in matrixed organizations, the ability to adapt to new therapeutic modalities, and experience building relationships with thought leaders. Experience in managing vendor partners and excellent written and verbal communication skills are also necessary.

Responsibilities

The Director will be accountable for developing and executing a comprehensive publication and medical education strategy, including planning congress strategy, creating internal and external medical education materials, and overseeing scientific review and approval of communication materials. They will also assist in developing global medical communications initiatives, provide medical oversight, serve as an internal expert on medical literature, partner with Patient Advocacy and regional medical teams, maintain scientific communications platforms, and collaborate with the Global Medical Affairs team to ensure alignment on program priorities.

Skills

Scientific Publications

Medical Education

Strategic Planning

Medical Communication

Internal and External Medical Materials

Cross-functional Collaboration

Regulatory Compliance

Dyno Therapeutics

Develops AI-optimized gene therapy vectors

About Dyno Therapeutics

Dyno Therapeutics focuses on advancing gene therapy by utilizing Artificial Intelligence to create Adeno-associated virus (AAV) vectors. These vectors are essential tools for delivering genetic material into cells, which is crucial for effective gene therapy. The company's AI technology enables the design and optimization of these vectors, potentially enhancing the success of gene therapies. Dyno collaborates with major pharmaceutical and biotech companies, such as Astellas, Roche, Sarepta, and Novartis, to develop therapies for various diseases affecting the skeletal and cardiac muscles, central nervous system, liver, and eyes. Unlike many competitors, Dyno's unique approach leverages AI to improve the performance of AAV vectors, setting it apart in the biotech field. The company's goal is to improve gene therapy outcomes through its advanced vector technology, ultimately benefiting patients with serious health conditions.

Watertown, MassachusettsHeadquarters

2018Year Founded

$106MTotal Funding

SERIES_ACompany Stage

AI & Machine Learning, Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Remote Work Options

Risks

Gene therapy investment slowdown may impact Dyno's growth and innovation.

Manufacturing bottlenecks could hinder scaling of Dyno's operations.

Increased competition from companies like Form Bio challenges Dyno's market position.

Differentiation

Dyno uses AI to design optimized AAV vectors for gene therapy.

Their AI-driven CapsidMap platform enhances AAV vector development for muscle gene therapies.

Partnerships with major pharma companies like Astellas and Roche boost Dyno's market presence.

Upsides

AI-driven capsid design improves delivery efficiency and reduces manufacturing costs.

Collaboration with NVIDIA enhances biological sequence design for gene therapies.

Generative AI increases efficiency of eye and brain-targeted capsid delivery significantly.

Land your dream remote job 3x faster with AI

Try Jobo Free